Subsequent gene expression profiling studies identified FLT3 as one of the most upregulated genes distinguishing KMT2A-r ALL from non-KMT2A-r ALL and acute myeloid leukemia (AML)4, and its therapeutic potential has been extensively explored in laboratory models and patients5–7. Here, FLT3 is linked to acute myeloid leukemia.